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Abstract
Introduction: This open-label pilot study aimed to investigate the efficacy of canakinumab in colchicine-resistant
familial Mediterranean fever (FMF) patients.
Method: Patients with one or more attacks in a month in the preceding 3 months despite colchicine were eligible
to enter a 30-day run-in period. Patients who had an attack during the first run-in period advanced to a second
30-day period. At the first attack, patients started to receive three canakinumab 150 mg subcutaneous injections at
4-week intervals, and were then followed for an additional 2 months. Primary efficacy outcome measure was the
proportion of patients with 50 % or more reduction in attack frequency. Secondary outcome measures included
time to next attack following last canakinumab dose and changes in quality of life assessed by SF-36.
Results: Thirteen patients were enrolled in the run-in period and 9 advanced to the treatment period. All 9 patients
achieved a 50 % or more reduction in attack frequency, and only one patient had an attack during the treatment
period. C-reactive protein and serum amyloid A protein levels remained low throughout the treatment period.
Significant improvement was observed in both physical and mental component scores of the Short Form-36 at Day
8. Five patients had an attack during the 2-month follow-up, occurring median 71 (range, 31 to 78) days after the
last dose. Adverse events were similar to those observed in the previous canakinumab trials.
Conclusion: Canakinumab was effective at controlling the attack recurrence in patients with FMF resistant to
colchicine. Further investigations are warranted to explore canakinumab’s potential in the treatment of patients
with colchicine resistant FMF.
Trial registration: ClinicalTrials.gov NCT01088880. Registered 16 March 2010.
Introduction
Familial Mediterranean fever (FMF), the most common
form of hereditary autoinflammatory disorder, is charac-
terized by recurrent attacks of fever with serosal or syn-
ovial inflammation, generally lasting 12 to 72 hours [1].
It has also been associated with increased risk of second-
ary amyloidosis, mainly affecting renal and vascular
function in untreated or insufficiently treated patients
with FMF.
Colchicine, the standard of care for patients with FMF,
has been considered as safe and effective in the majority
of the patients for reducing both the frequency of
inflammatory episodes and the risk of developing amyl-
oidosis [2–4]. However, there are currently no effective
and approved alternatives for FMF patients who are
intolerant to colchicine, and dose reductions due to
adverse effects may result in diminished efficacy. In
addition, approximately 5−10 % of patients with FMF
continue to have frequent inflammatory episodes despite
receiving the highest tolerable doses (1.5 to 2.0 mg/day)
of colchicine, which are considered to be within the ef-
fective range.
The majority of FMF patients have autosomal reces-
sive inheritance associated with mutations in the MEFV
gene, which encodes pyrin protein [1]. FMF-related
MEFV mutations, which affect pyrin-mediated regula-
tion of caspase 1 activity in the inflammasomes, are
* Correspondence: agul@istanbul.edu.tr
1Istanbul Faculty of Medicine, Department of Internal Medicine, Division of
Rheumatology, 34093 Fatih Istanbul, Turkey
Full list of author information is available at the end of the article
© 2015 Gül et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Gül et al. Arthritis Research & Therapy  (2015) 17:243 
DOI 10.1186/s13075-015-0765-4
associated with increased IL-1β production in mice and
humans [1]. Therefore, inhibition of IL-1 activity may
decrease both frequency and severity of acute attacks in
patients with FMF. Several reports of patients with FMF
being successfully treated with agents blocking IL-1 ac-
tivity, mainly with daily injections of the recombinant
form of IL-1 receptor antagonist (IL-1Ra), anakinra, have
confirmed the critical role of IL-1 in the pathogenesis
FMF [5, 6].
The objective of this study was to evaluate the efficacy
and safety of canakinumab, a fully human anti-IL-1β
monoclonal antibody with a half-life of approximately 4
weeks, that binds to human IL-1β and neutralizes its
proinflammatory effects, in adolescent and adult patients
with FMF, who are resistant or intolerant to higher doses
of colchicine.
Methods
The present study was an investigator-initiated, open-
label exploratory trial that included adolescent and adult
FMF patients with active disease despite receiving the
highest tolerable doses of colchicine (1.5 to 2.0 mg/day).
All patients had a typical type I phenotype, fulfilling the
criteria for FMF diagnosis [7], along with at least one of
the exon 10 mutations in the MEFV gene. Patients with
end-organ dysfunction due to secondary amyloidosis, ac-
tive tuberculosis or any other infectious diseases, or a
history of malignancy within the last 5 years were ex-
cluded from the study.
Colchicine-compliant patients with a history of one or
more attacks per month within 3 months before the
screening were eligible to enter the first 30-day run-in
period. Patients who had at least one attack during that
period advanced to a second 30-day period, and they re-
ceived their first dose of canakinumab upon the first at-
tack they experienced during this second 30-day run-in
period.
The treatment period started with the first injection,
and patients received a total of three subcutaneous injec-
tions of canakinumab 150 mg at 4-week intervals. The
canakinumab dose could be increased to 300 mg, if an
attack occurred between the first and second doses.
Stable doses of colchicine (1.5 to 2.0 mg/day) were
allowed throughout the study without any dose modifi-
cation, and compliance was followed tightly throughout
the study. After the 12-week treatment period, the pa-
tients were subsequently followed for up to 2 months or
until the next attack.
FMF attacks were confirmed by presence of fever,
clinical findings of serositis/arthritis, and elevated C-
reactive protein (CRP) levels. Details of each attack
(duration, type, severity, maximum body temperature)
were recorded in diaries. Diaries were dispensed to
the colchicine-resistant FMF (crFMF) patients at each
visit to record the occurrence of any attacks between
the scheduled visits.
The primary outcome measure was the proportion of
patients with 50 % or more reduction in time-adjusted fre-
quency of attacks. Due to the unequal pre-treatment and
treatment periods, attack rates were adjusted to the 84-
day treatment period compared with the pre-treatment
periods. Secondary outcome measures included the per-
centage of patients with no attacks in the treatment
period, time to next attack after the last canakinumab ad-
ministration, changes in quality of life assessed by the 36-
item short-form health survey (SF-36), and serum levels of
CRP and serum amyloid A (SAA) proteins. Physicians’
and patients’ global assessments of control of FMF since
the last visit and response to treatment at the end of the
treatment period were also measured using a modified 5-
point scale [8]. All adverse events and laboratory values
were recorded at each visit for the assessment of safety of
canakinumab treatment.
Istanbul Faculty of Medicine Ethics Committee and
Ministry of Health approved the study protocol, and all
patients provided written informed consent before the
screening. Exploratory analyses were performed using
descriptive statistics.
Results and discussion
A total of 13 patients with crFMF were screened and in-
cluded in the first 30-day run-in period. Nine patients
(median age 22 years, range, 12 to 34) had ≥1 attack
during that period, advancing to the second 30-day
period, and began their treatment period by starting
canakinumab treatment at the first observed attack
within this period. Patient baseline demographic charac-
teristics and MEFV genotypes are summarized in
Additional file 1: Table S1.
All nine patients in the treatment period achieved the
primary endpoint of ≥50 % reduction in frequency of at-
tacks compared with the time-adjusted pre-treatment
frequency of attacks. During the treatment period, only
one patient, who was p.Met694Val homozygous and re-
ceiving 2 mg/day colchicine, had an attack of peritonitis
on day 54. No patient qualified for a canakinumab dose
increase between the first and second injections. The
time-adjusted frequency of attacks over 84 days observed
in the screening and run-in periods, including the baseline
attack (median 3.29, range 2.47 to 4.2), decreased dramat-
ically during the treatment period (median 0, mean 0.11).
Five patients, all p.Met694Val homozygous and receiv-
ing 2 mg/day colchicine, subsequently experienced an at-
tack within the 2-month follow up, which occurred at a
median 71 days (range 31 to 78 days) after the last cana-
kinumab injection (Fig. 1). Median baseline CRP and
SAA levels (58 mg/L and 162 mg/L, respectively) on day
1 of canakinumab administration normalized (2.5 mg/L
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and 5.8 mg/L, respectively) by day 8, and remained low
throughout the study (Additional file 2: Figure S1). No
other significant laboratory abnormalities were noted.
The median SF-36 physical and mental component
scores increased dramatically at day 8 compared with
baseline scores and continued to improve throughout
the treatment period (Additional file 3: Figure S2). Com-
pared with baseline, the physician’s and patient’s global
assessment of crFMF control improved with canakinu-
mab treatment, and overall treatment response was re-
ported as being very good both by physicians (for all
patients) and patients (seven of nine patients) at the end
of study (Fig. 2).
Eight patients reported at least one adverse event; head-
ache (n = 4) and upper respiratory tract infection (n = 2)
were the only adverse events reported by more than one
patient (Table 1). All adverse events were mild or moder-
ate except one, which was a severe headache. None of the
patients discontinued the trial due to an adverse event. A
mild, local injection-site reaction was recorded in two pa-
tients on at least one occasion.
One of the patients became pregnant during the treat-
ment period after the third canakinumab dose and gave
birth to a healthy son.
This open-label pilot trial showed that monthly cana-
kinumab 150 mg subcutaneous injections prevented at-
tacks in patients with crFMF, and only one of nine
patients experienced an attack during canakinumab
treatment. The safety profile of canakinumab in this
small group of patients was similar to that of larger con-
trolled trials in other hereditary autoinflammatory con-
ditions [8–10].
Colchicine has long been used to prevent inflammatory
attacks and reduce the risk of secondary amyloidosis in
patients with FMF. Despite the efficacy of colchicine,
some manifestations, such as arthritis, are less responsive
to colchicine [11]. Furthermore, 5−10 % of patients are
non-responders to colchicine [12], and the number of
Fig. 1 Number and severity of familial Mediterranean fever attacks observed throughout the study period. Severity of the attack was assessed
according to patients’ assessment in relation to their previous experiences
Fig. 2 Physician’s global assessment of control of familial Mediterranean fever over the previous month. EOS end of study
Gül et al. Arthritis Research & Therapy  (2015) 17:243 Page 3 of 5
FMF patients who are either intolerant or resistant to col-
chicine and continue to experience frequent and/or severe
inflammatory attacks is increasing [13].
Given the association of type and number of MEFV
variations with increased production of IL-1β, several
case reports of patients treated with either anakinra or
canakinumab have suggested the potential efficacy of IL-
1 blockade in colchicine-resistant patients and those
with amyloidosis [5, 6]. Additionally, in a recent ran-
domized, double-blind, alternating-treatment trial the
frequency of attacks decreased with weekly injections of
rilonacept, another anti-IL-1 drug, consisting of human-
ized IL-1 type 1 receptor, IL-1 receptor accessory protein
and the Fc portion of IgG1 [14]. All three drugs block
IL-1 beta activity, but there are some differences, mainly
resulting from the half-lives of these drugs, the shortest
being for anakinra, requiring injections at least once
daily, and the longest being for canakinumab, requiring
monthly or bi-monthly injection intervals, which may
affect the quality of life of patients. There is no study
comparing the dynamics of IL-1 beta secretion in pa-
tients with crFMF with those in patients with cryopyrin-
associated periodic fever syndrome (CAPS) [8, 9]. There-
fore, in this pilot trial, we aimed to test the efficacy and
safety of canakinumab in patients with crFMF by 4-weekly
administration intervals for 3 months and followed
them up for 2 months to observe any recurrence of
inflammatory attacks. In this follow-up period there
was an inter-individual variability in the timing of re-
current attacks, with a range of 31 to 78 days after
the last dose in five patients, and possibly reflecting
differences in their inflammatory activity. Randomized
controlled trials are expected to provide further data
about the optimum dosage and administration inter-
vals of canakinumab in patients with crFMF.
The limitations of this small exploratory study were its
open-label design, relatively short treatment period, and
lack of formal definitions for disease severity and colchi-
cine resistance. However, inclusion of mainly patients
with FMF with two penetrant mutations and ≥1 attack
per month despite receiving the highest tolerable doses
of colchicine, together with confirmation of attacks and
colchicine-compliance during the run-in period, repre-
sent a real-world patient cohort with few treatment
options.
Conclusions
In conclusion, the results of the present pilot trial sug-
gest that canakinumab may be an effective and safe
treatment option for colchicine-resistant and colchicine-
intolerant patients with FMF, and warrant further inves-
tigations to explore its efficacy, safety and optimum dos-
age and administration intervals in this subset of FMF
patients.
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Table 1 Adverse events observed in nine patients during the
canakinumab treatment period
Number (%)
Adverse events 8 (88.9)






Tooth infection 1 (11.1)
Upper respiratory tract infection 2 (22.2)
Vomiting 1 (11.1)
aThis patient had a medical history of hidradenitis, and she had no serious
exacerbation during canakinumab treatment
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